title: The role of diagnosis in patients failing peripheral blood progenitor cell mobilization.
abstract: BACKGROUND
  Failure to mobilize PBPCs for auto-logous transplantation has mostly been attributed to previous therapy and poses therapeutic problems.
  
  
  METHODS
  The role of underlying disease was analyzed in 17 of 73 (23%) patients with PBPC mobilization failure, and secondary mobilization with high-dose filgrastim was attempted.
  
  
  RESULTS
  Of 16 patients with acute leukemia, 13 (81%) mobilized poorly. In contrast, of 57 patients with non-Hodgkin's lymphoma, Hodgkin's lymphoma, multiple myeloma, and solid tumor, 53 (93%, p < 0.001) showed good PBPC mobilization. Relapsed disease did not predispose to poor mobilization. As secondary mobilization attempt, 7 patients received 25 micro g per kg per day filgrastim without chemotherapy leading to a 3.7 +/- 2.8-fold (SD) increase in the maximum number of circulating CD34+ cells (p = 0.104). PBPC apheresis yielded 3.3 (+/-0.5) x 10(6) CD34+ cells per kg of body weight in 5 patients. Four poor mobilizers received 50 micro g per kg per day filgrastim as second or third mobilization attempt. Circulating CD34+ cells in these patients increased by 1.5 (+/-0.7) compared with the primary G-CSF application.
  
  
  CONCLUSIONS
  Selective PBPC mobilization failure was seen in patients with acute leukemia whereas remarkably good mobilization was seen in other malignancies. Increasing the filgrastim dose to 25 micro g per kg per day may allow PBPC collection in patients failing PBPC mobilization.
authors.affiliation: Clinic of Hematology/Oncology, Institute for Transfusion Medicine and Immunohematology, Otto-von-Guericke University, Magdeburg, Germany. michael.koenigsmann@medizin.uni-magdeburg.de
authors.forename: Michael
authors.initials: M
authors.lastname: Koenigsmann
authors.forename: Kathleen
authors.initials: K
authors.lastname: Jentsch-Ullrich
authors.forename: Martin
authors.initials: M
authors.lastname: Mohren
authors.forename: Elke
authors.initials: E
authors.lastname: Becker
authors.forename: Marcell
authors.initials: M
authors.lastname: Heim
authors.forename: Astrid
authors.initials: A
authors.lastname: Franke
mesh_terms: D000328:Adult; D018952:Antigens, CD34 / Q000032:analysis; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007938:Leukemia / Q000628:therapy; D008223:Lymphoma / Q000628:therapy; D008875:Middle Aged; D011994:Recombinant Proteins
chemical_list: D018952:Antigens, CD34; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim